Aptevo Therapeutics

83 articles with Aptevo Therapeutics

• Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

  1/9/2023

  Aptevo Therapeutics Inc. today announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon.

• 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

  12/12/2022

  Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naive.

• Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

  9/19/2022

  Alligator Bioscience AB today announced that the US Food and Drug Administration (FDA) has issued a notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.

• Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

  8/11/2022

  Aptevo Therapeutics Inc. today reported financial results and business highlights for the quarter ended June 30, 2022.

• Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

  6/9/2022

  Aptevo Therapeutics Inc. today announced new remission data on four additional patients.

• Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

  5/12/2022

  Aptevo Therapeutics Inc. today reported financial results and business highlights for the quarter ended March 31, 2022.

• APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

  4/12/2022

  Aptevo Therapeutics Inc. today announced the presentation of preclinical data for APVO442 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.

• Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

  3/29/2022

  Aptevo Therapeutics Inc. today announced that a patient with relapsed/refractory acute myeloid leukemia or AML in a monotherapy arm of its on-going Phase 1b trial evaluating adult patients with AML, has received an allogeneic stem cell transplant subsequent to receiving APVO436 and experiencing significant reduction in bone marrow blasts.

• Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

  3/24/2022

  Aptevo Therapeutics Inc. today reported its financial results for the year ended December 31, 2021 and provided 2021 business highlights.

• Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

  2/9/2022

  Aptevo Therapeutics Inc. today announced that the Company has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE®.

• Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

  1/21/2022

  Aptevo Therapeutics Inc. today announced that founding chairman of the board, Fuad El-Hibri, has announced his retirement effective April 1, 2022. The Company also announced that long-time board member and vice chairman John E. Niederhuber, M.D., will assume the chairmanship, effective April 1, 2022.

• Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication

  12/15/2021

  Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications on the mechanism of action of CD137 (4-1BB) targeting bispecific antibodies.

• Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

  12/15/2021

  Alligator Bioscience AB today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies.

• 

  Clinical Catch-Up: November 22-26

  11/29/2021

  Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.

• Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

  11/23/2021

  Aptevo Therapeutics Inc. today announced a clinical update for the Company's Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia (AML).

• 

  Aptevo Soars on Reports of Complete Remission in AML

  11/23/2021

  Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.

• Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting

  11/15/2021

  Aptevo Therapeutics Inc. today announced that the Company will present two abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

• Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

  11/12/2021

  Aptevo Therapeutics Inc. today reported its financial results and business highlights for the quarter ended September 30, 2021.

• Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting

  11/11/2021

  Aptevo Therapeutics Inc. today announced the presentation of preclinical data for APVO603, the Company's bispecific antibody targeting 4-1BB (CD137) and OX40 (CD134), at the Society for Immunology in Cancers (SITC) 2021 Annual Meeting.

• Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021

  10/27/2021

  Aptevo Therapeutics Inc. and ADAPTIR-FLEX platform technologies, will participate at the 2nd Virtual Congress on Controversies in Leukemias (EuroLeuk), an international leukemia symposium which is being held October 28-29, 2021